Mercer Global Advisors
VIR icon

Mercer Global Advisors’s Vir Biotechnology VIR Stock Holding History

Mercer Global Advisors’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$268K Buy
+29,940
New +$239K ﹤0.01% 2551
2023
Q3 		– Sell
-47,560
Closed -$1.17M – 2062
2023
Q2 		$1.17M Buy
47,560
+7,831
+20% +$197K ﹤0.01% 895
2023
Q1 		$924K Buy
39,729
+3,865
+11% +$98.9K ﹤0.01% 944
2022
Q4 		$908K Buy
35,864
+1,414
+4% +$34.7K ﹤0.01% 960
2022
Q3 		$664K Buy
+34,450
New +$876K ﹤0.01% 1017

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Mercer Global Advisors's VIR Position: Q1 2026 in Review

Mercer Global Advisors opened a new position in Vir Biotechnology (VIR) in Q1 2026: 29,940 shares worth $268K. The stake represents ﹤0.01% of the portfolio and ranks #2551 among its holdings. This is a return to the name: Mercer Global Advisors previously reported a position in VIR as recently as Q2 2023.

Mercer Global Advisors first reported a position in VIR in Q3 2022 and has held it in 5 quarters since. The position peaked at $1.17M in Q2 2023. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Mercer Global Advisors held 29,940 shares of Vir Biotechnology worth $268K as of Q1 2026.
  • Vir Biotechnology was a new Mercer Global Advisors position in Q1 2026.
  • Vir Biotechnology made up ﹤0.01% of Mercer Global Advisors's portfolio in Q1 2026, its #2551 holding.
  • Mercer Global Advisors first reported a position in Vir Biotechnology in Q3 2022 and has held it in 5 quarters since.
  • Mercer Global Advisors's Vir Biotechnology position peaked at $1.17M in Q2 2023.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.